Table 2.
Clinical characteristics of ISR and NISR groups.
| Variables | ISR (n = 21) | NISR (n = 26) | P value |
|---|---|---|---|
| Dyslipidemia % | 71.4 | 46.2 | 0.081 |
| Diabetics % | 61.9 | 46.2 | 0.282 |
| Hypertension % | 71.4 | 65.4 | 0.659 |
| Stent type % | |||
| Bare | 50.0 | 11.1 | 0.015∗ |
| Drug | 50.0 | 88.9 | |
| Stent number % | |||
| 1 | 66.7 | 65.4 | 0.927 |
| >1 | 33.3 | 34.6 | |
| De novo stenosis in other vessels % | 57.1 | 60.9 | 0.802 |
| Duration of stent implantation (month) | 32.8 ± 5.9 | 22.4 ± 5.4 | 0.200 |
| Ejection fraction (%) | 46.2 ± 2.9 | 45.2 ± 2.5 | 0.806 |
| hs-CRP (mg/L) | 3.90 ± 0.8 | 4.62 ± 0.8 | 0.509 |
| Drugs consumption % | |||
| Statin | 100.0 | 88.0 | 0.239 |
| Aspirin | 90.5 | 84.0 | 0.257 |
| Clopidogrel | 68.4 | 92.0 | 0.095 |
| NSAID | 15.0 | 4.0 | 0.197 |
| β blocker | 5.9 | 12.5 | 0.555 |
| ARB | 58.8 | 50.0 | |
| ACE inhibitor | 29.4 | 12.5 | |
| CCB | 5.9 | 18.8 | |
| Insulin | 19.0 | 19.2 | 0.324 |
| Oral diabetic drugs | 38.1 | 19.2 |
Data are expressed as mean ± SE or percentage; ∗statistically significant (P < 0.05). ISR: in-stent restenosis; NIRS: non-in-stent restenosis; hs-CRP: high-sensitivity C-reactive protein; ARB: angiotensin receptor blockers; ACE: angiotensin converting enzyme; CCB: channel calcium blocker; NSAID: nonsteroidal anti-inflammatory drugs.